Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules

Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms

90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement Scale Total Score

INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor that allows patients to start immediately at a therapeutic dose without required titration

SAN DIEGO , Oct. 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT ® 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once-daily INGREZZA ® (valbenazi